Capricor to Give Update on HOPE-2 Clinical Trial for CAP-1002 at International Conference on Duchenne Muscular Dystrophy
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: GlobeNewswire
LOS ANGELES, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) will provide an update on HOPE-2, its trial for CAP-1002, the company’s lead investigational therapy for the treatment of Duchenne muscular dystrophy, at the 16th International Conference on Duchenne and Becker Muscular Dystrophy taking place in Rome this Friday through Sunday. The three-day conference brings together scientists, physicians, companies, patients and their families to discuss the latest developments in Duchenne and Becker muscular dystrophy. Linda Marbán, Ph.D., Capricor president and chief executive officer, will provide a presentation on Sunday on HOPE-2, a randomized, double-blind, placebo-controlled clinical trial anticipated to begin enrolling participants in March. “Our previous clinical trial, the HOPE-Duchenne Trial, found significant and sustained improvements in skeletal muscle function and cardiac structure following a single dose of intracoronary CAP-1002,” said Dr. Marbán
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Thinking about buying stock in Curiositystream, Capricor Therapeutics, PowerFleet, Absci, or Nano-X Imaging?PR Newswire
- Capricor Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswire
- Earnings Beat: Capricor Therapeutics, Inc. (NASDAQ:CAPR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts [Yahoo! Finance]Yahoo! Finance
- Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect? [Yahoo! Finance]Yahoo! Finance
CAPR
Earnings
- 2/29/24 - Beat
CAPR
Analyst Actions
- 3/1/24 - HC Wainwright
CAPR
Sec Filings
- 4/1/24 - Form ARS
- 4/1/24 - Form DEF
- 3/20/24 - Form PRE
- CAPR's page on the SEC website